The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Central nervous system (CNS) portfolio from Sanofi
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company
![Denmark Denmark flag](https://www.greenhill.com/sites/default/files/denmark_flag%5B1%5D.gif)
Global collaboration agreement with Genmab A/S
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
![Sweden Sweden flag](https://www.greenhill.com/sites/default/files/sweden.gif)
Unfors Raysafe AB
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
![Sweden Sweden flag](https://www.greenhill.com/sites/default/files/sweden.gif)
Biotage (Biosystems division)
![Netherlands Netherlands flag](https://www.greenhill.com/sites/default/files/niederland.gif)
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research